13280-03-0

Basic information

• Product Name: chlorotetrolic acid
• Synonyms: chlorotetrolic acid;4-chloro-2-Butynoic acid
• CAS NO: 13280-03-0
• Molecular Formula: C₄H₃ClO₂
• Molecular Weight: 118.52
• Mol File: 13280-03-0.mol

Chemical Properties

• Boiling Point: 263.5°Cat760mmHg
• Flash Point: 113.2°C
• Appearance: /
• Density: 1.413g/cm³
• Vapor Pressure: 0.00301mmHg at 25°C
• Refractive Index: 1.507
• PKA: 2.09±0.10(Predicted)
• CAS DataBase Reference: chlorotetrolic acid(CAS DataBase Reference)
• NIST Chemistry Reference: chlorotetrolic acid(13280-03-0)
• EPA Substance Registry System: chlorotetrolic acid(13280-03-0)

Safety Data

• Hazardous Substances Data: 13280-03-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C4H3ClO2/c5-3-1-2-4(6)7/h3H2,(H,6,7)

Upstream product

• 624-65-7 2-propynyl chloride 
• 124-38-9 carbon dioxide 
• 13280-07-4 4-chlorobut-2-yn-1-ol 

Downstream Products

• 38346-95-1 4-morpholin-4-yl-but-2-ynoic acid 
• 41658-12-2 Chlortetrolsaeuremethylester 
• 75707-02-7 (E)-3,4-dichlorobut-2-enoic acid 
• 75707-02-7 (Z)-3,4-dichlorobut-2-enoic acid 
• 93524-35-7 p-Nitrophenyl 4-Chloro-2-butynoate 
• 104503-38-0 5-Chloromethyl-1-(4-chloro-phenyl)-1H-[1,2,3]triazole-4-carboxylic acid 

Relevant articles and documents

Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors

This invention provides compounds of formula 1 wherein R1, G1, G2, R4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS

This invention provides compounds of formula (1) wherein X is C3-7 cycloalkyl, pyridinyl, pyrimidinyl or phenyl ring optionally substituted as described in claim 1, R1, R3 and R4 are chosen from the groups listed in claim 1. R2 is chosen from various unsaturated acyl groups listed in claim 1, with certain compounds being disclaimed. Use as tyrosine kinase inhibitors for the treatment of cancer and certain kidney diseases such as polycystic kidney disease.

SUBSTITUTED-3-CYANO-[1.7],[1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES

This invention provides compounds of formula (I) having structure (a) wherein A'' is a diavalent moiety selected from the group (a, b, c) which are useful as inhibitors of protein tyrosine kinase.

SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS

This invention provides compounds of formula (1) wherein R1, G1, G2, R4, Z, X and n are defined herein, or a pharmaceutically acceptable salt thereof, which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

Substituted 3-cyanoquinolines

This invention provides compounds of formula I having the structure wherein G1, G2, R1, R4, Z, n, and X are defined in the specification or a pharmaceutically acceptable salt thereof which are useful as antineoplastic agents and in the treatment of polycystic kidney disease.

Substituted quinazoline derivatives

This invention provides compounds of formula 1 having the structure wherein: X, R1, R2, R3, R4, Z, X, and n are as defined hereinbefore in the specification, which are useful as antineoplastic agents and in the treatment of certain kidney diseases, such as polycystic kidney disease.

Dihydropyridazinones, pyridazinones and related compounds as fungicides

This invention relates to substituted dihydropyridazinones, pyridazinones and related compounds, of the formula STR1 wherein A, Q, D and R1 are as defined within, compositions containing these compounds and methods of controlling agricultural and mammalian fungal diseases.